188 related articles for article (PubMed ID: 10385711)
1. Thyrotropin receptor: a role for thyroid tumourigenesis?
Russo D; Arturi F; Chiefari E; Filetti S
Forum (Genova); 1999; 9(2):166-75. PubMed ID: 10385711
[TBL] [Abstract][Full Text] [Related]
2. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
Paschke R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
[TBL] [Abstract][Full Text] [Related]
3. Enhanced functional activity in thyroid adenomas in vitro.
Poertl S; Kirner J; Mann K; Hoermann R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():39-40. PubMed ID: 8980999
[TBL] [Abstract][Full Text] [Related]
4. Activating mutations of the TSH receptor in differentiated thyroid carcinomas.
Russo D; Arturi F; Schlumberger M; Caillou B; Monier R; Filetti S; Suárez HG
Oncogene; 1995 Nov; 11(9):1907-11. PubMed ID: 7478621
[TBL] [Abstract][Full Text] [Related]
5. Constitutively activating mutations of the thyrotropin receptor and thyroid disease.
Führer D; Holzapfel HP; Wonerow P; Paschke R
Eur J Med Res; 1996 Jul; 1(10):460-4. PubMed ID: 9438142
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.
Parma J; Duprez L; Van Sande J; Cochaux P; Gervy C; Mockel J; Dumont J; Vassart G
Nature; 1993 Oct; 365(6447):649-51. PubMed ID: 8413627
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells.
Fournes B; Monier R; Michiels F; Milgrom E; Misrahi M; Feunteun J
Oncogene; 1998 Feb; 16(8):985-90. PubMed ID: 9519872
[TBL] [Abstract][Full Text] [Related]
8. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.
Du Villard JA; Wicker R; Crespo P; Russo D; Filetti S; Gutkind JS; Sarasin A; Suárez HG
Oncogene; 2000 Oct; 19(42):4896-905. PubMed ID: 11039907
[TBL] [Abstract][Full Text] [Related]
9. Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features.
Arturi F; Capula C; Chiefari E; Filetti S; Russo D
Exp Clin Endocrinol Diabetes; 1998; 106(3):234-6. PubMed ID: 9710366
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms.
Derwahl M; Manole D; Sobke A; Broecker M
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 4():S6-9. PubMed ID: 9867188
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
[TBL] [Abstract][Full Text] [Related]
12. Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells.
Porcellini A; Ruggiano G; Pannain S; Ciullo I; Amabile G; Fenzi G; Avvedimento EV
Oncogene; 1997 Aug; 15(7):781-9. PubMed ID: 9266964
[TBL] [Abstract][Full Text] [Related]
13. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation.
Spambalg D; Sharifi N; Elisei R; Gross JL; Medeiros-Neto G; Fagin JA
J Clin Endocrinol Metab; 1996 Nov; 81(11):3898-901. PubMed ID: 8923835
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas.
Porcellini A; Ciullo I; Pannain S; Fenzi G; Avvedimento E
Oncogene; 1995 Sep; 11(6):1089-93. PubMed ID: 7566968
[TBL] [Abstract][Full Text] [Related]
15. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid.
Paschke R; Tonacchera M; Van Sande J; Parma J; Vassart G
J Clin Endocrinol Metab; 1994 Dec; 79(6):1785-9. PubMed ID: 7989485
[TBL] [Abstract][Full Text] [Related]
16. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma.
Tonacchera M; Chiovato L; Pinchera A; Agretti P; Fiore E; Cetani F; Rocchi R; Viacava P; Miccoli P; Vitti P
J Clin Endocrinol Metab; 1998 Feb; 83(2):492-8. PubMed ID: 9467563
[TBL] [Abstract][Full Text] [Related]
17. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms.
Matsuo K; Friedman E; Gejman PV; Fagin JA
J Clin Endocrinol Metab; 1993 Jun; 76(6):1446-51. PubMed ID: 8501149
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous distribution of thyrotrophin receptor messenger ribonucleic acid (TSH-R mRNA) in papillary thyroid carcinomas detected by in situ hybridization.
Tanaka K; Inoue H; Miki H; Komaki K; Monden Y
Clin Endocrinol (Oxf); 1996 Mar; 44(3):259-67. PubMed ID: 8729520
[TBL] [Abstract][Full Text] [Related]
19. TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5.
Karges B; Krause G; Homoki J; Debatin KM; de Roux N; Karges W
J Endocrinol; 2005 Aug; 186(2):377-85. PubMed ID: 16079263
[TBL] [Abstract][Full Text] [Related]
20. [Non-autoimmune hyperthyroidism and hyperfunctioning thyroid adenomas caused by activating mutation of the thyrotropin receptor].
Kosugi S
Nihon Rinsho; 2002 Feb; 60(2):291-6. PubMed ID: 11857916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
